Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

por Herbst, Roy S., Soria, Jean-Charles, Kowanetz, Marcin, Fine, Gregg D., Hamid, Omid, Gordon, Michael S., Sosman, Jeffery A., McDermott, David F., Powderly, John D., Gettinger, Scott N., Kohrt, Holbrook E. K., Horn, Leora, Lawrence, Donald P., Rost, Sandra, Leabman, Maya, Xiao, Yuanyuan, Mokatrin, Ahmad, Koeppen, Hartmut, Hegde, Priti S., Mellman, Ira, Chen, Daniel S., Hodi, F. Stephen
Publicado no Nature (2014)

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 t...

por Rosenberg, Jonathan E., Hoffman-Censits, Jean, Powles, Tom, van der Heijden, Michiel S., Balar, Arjun V., Necchi, Andrea, Dawson, Nancy, O’Donnell, Peter H., Balmanoukian, Ani, Loriot, Yohann, Srinivas, Sandy, Retz, Margitta M., Grivas, Petros, Joseph, Richard W., Galsky, Matthew D., Fleming, Mark T., Petrylak, Daniel P., Perez-Gracia, Jose Luis, Burris, Howard A., Castellano, Daniel, Canil, Christina, Bellmunt, Joaquim, Bajorin, Dean, Nickles, Dorothee, Bourgon, Richard, Frampton, Garrett M., Cui, Na, Mariathasan, Sanjeev, Abidoye, Oyewale, Fine, Gregg D., Dreicer, Robert
Publicado no Lancet (2016)

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

por McDermott, David F., Huseni, Mahrukh A., Atkins, Michael B., Motzer, Robert J., Rini, Brian I., Escudier, Bernard, Fong, Lawrence, Joseph, Richard W., Pal, Sumanta K., Reeves, James A., Sznol, Mario, Hainsworth, John, Rathmell, W. Kimryn, Stadler, Walter M., Hutson, Thomas, Gore, Martin E., Ravaud, Alain, Bracarda, Sergio, Suárez, Cristina, Danielli, Riccardo, Gruenwald, Viktor, Choueiri, Toni K., Nickles, Dorothee, Jhunjhunwala, Suchit, Piault-Louis, Elisabeth, Thobhani, Alpa, Qiu, Jiaheng, Chen, Daniel S., Hegde, Priti S., Schiff, Christina, Fine, Gregg D., Powles, Thomas
Publicado no Nat Med (2018)

Atezolizumab as first-line therapy in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

por Balar, Arjun V, Galsky, Matthew D, Rosenberg, Jonathan E, Powles, Thomas, Petrylak, Daniel P, Bellmunt, Joaquim, Loriot, Yohann, Necchi, Andrea, Hoffman-Censits, Jean, Perez-Gracia, Jose Luis, Dawson, Nancy A, van der Heijden, Michiel S, Dreicer, Robert, Srinivas, Sandy, Retz, Margitta M, Joseph, Richard W, Drakaki, Alexandra, Vaishampayan, Ulka N, Sridhar, Srikala S, Quinn, David I, Durán, Ignacio, Shaffer, David R, Eigl, Bernhard J, Grivas, Petros D, Yu, Evan Y, Li, Shi, Kadel, Edward E, Boyd, Zachary, Bourgon, Richard, Hegde, Priti S, Mariathasan, Sanjeev, Thåström, AnnChristine, Abidoye, Oyewale O, Fine, Gregg D, Bajorin, Dean F
Publicado no Lancet (2016)

TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

por Mariathasan, Sanjeev, Turley, Shannon J., Nickles, Dorothee, Castiglioni, Alessandra, Yuen, Kobe, Wang, Yulei, Kadel, Edward E., Koeppen, Hartmut, Astarita, Jillian L., Cubas, Rafael, Jhunjhunwala, Suchit, Banchereau, Romain, Yang, Yagai, Guan, Yinghui, Chalouni, Cecile, Ziai, James, Şenbabaoğlu, Yasin, Santoro, Stephen, Sheinson, Daniel, Hung, Jeffrey, Giltnane, Jennifer M., Pierce, Andrew K., Mesh, Kathryn, Lianoglou, Steve, Riegler, Johannes, Carano, Richard A. D., Eriksson, Pontus, Hoglund, Mattias, Somarriba, Loan, Halligan, Daniel L., van der Heijden, Michiel, Loriot, Yohann, Rosenberg, Jonathan E., Fong, Lawrence, Mellman, Ira, Chen, Daniel S., Green, Marjorie, Derleth, Christina, Fine, Gregg D., Hegde, Priti S., Bourgon, Richard, Powles, Thomas
Publicado no Nature (2018)